Indications
Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.
Composition
- Active substance
- tolvaptan
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Jinarc
- Active substance
- tolvaptan
- ATC code
- C03XA01
- Therapeutic area
- Polycystic Kidney, Autosomal Dominant
- Marketing authorisation holder
- Otsuka Pharmaceutical Netherlands B.V.
- Status
- Authorised